Phase 2 N=95 A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain
Dysmenorrhea
Primary: Mean Change in Average Severity for Abdominal/Pelvic Pain — -0.45; -0.19 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage
Cerebral Vasospasm After Subarachnoid Hemorrhage
Primary: Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion) — -8; -3.4 mmHg
Phase 2 N=116 Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
Nocturia
Primary: Duration of Action Defined as the Time With Urine Osmolality Above 200 mOsm/kg - Period 1 — 0.00; 0.09; 2.00; 3.45 hours — p=0.211
Phase 2 N=176 Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months — 28.6; 42.7 Percentage of Participants — p=0.03
Phase 2 N=29 Safety and Effectiveness of the Device "Nit-Occlud® PDA-R"
Congenital Heart Disease
Primary: Number of Patients With a Closed Patent Ductus Arteriosus (Defect) Determinated by Echocardiography ( Time Frame: One Year After Treatment) — 19; 23; 28; 29 Participants…
Phase 2 N=60 Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
Asthma
Primary: Mean Area Under the Concentration Time Curve Over the Dosing Period (AUC[0-tau]) for FP — 376.9; 573.1; 350.5; 559.1 Picogram hours per milliliter (pg*h/mL)
Phase 2 N=27 Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol
Chronic Obstructive Pulmonary Disease
Primary: Percentage of Participants With Maximum Heart Rate Increase During Exercise in Part 1 of the Study — 20.00; 16.0 Percentage of participants
Phase 2 N=118 A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Non-Small-Cell Lung Carcinoma · Adenocarcinoma
Primary: Progression Free Survival (PFS) — 5.7; 6.1 Months — p=0.639
Phase 2 N=22 Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Lymphoma · Leukemia
Primary: 6-month Treatment Related Mortality (TRM)
Phase 2 N=487 Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
Seasonal Allergic Rhinitis · Hayfever
Primary: Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period — -1.88; -1.87; -2.22; -1.59 units on a scale…
Phase 2 N=1,594 Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over
Influenza
Primary: Haemagglutination Inhibition (HI) Antibody Titers for the H1N1 Vaccine Strain — 37.9; 40.1; NA; NA titer
Phase 2 N=10 Sildenafil for Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive · Emphysema
Primary: 6 Minute Walk Distance — 458.2; 466.1 meters
Phase 2 N=12 rTMS To The Dorsolateral Prefrontal Cortex For Patients With Subjective Idiopathic Tinnitus. A Pilot Study
Tinnitus
Primary: Average Change (Baseline-End of Treatment) Tinnitus Handicap Inventory (THI) — 10.7 units on a scale
Phase 2 N=7 Double-Blind Naltrexone in Compulsive Sexual Behavior
Compulsive Sexual Behavior
Primary: Yale Brown Obsessive Compulsive Scale Modified for Compulsive Sexual Behavior (YBOCS) — 8; 9.33 units on a scale
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…